HRA Pharma, a privately-held French pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, and Hyphens, a leading speciality pharmaceutical company in Southeast Asia that focuses on the sales and market development of innovative medical products, have entered into an exclusive licence and supply agreement to commercialize ella, HRA Pharma's next-generation emergency contraceptive, in Singapore and Malaysia.
Under the terms of the agreement, Hyphens will market ella exclusively in Singapore and Malaysia while HRA Pharma will be responsible for the manufacturing and supply of the product. Besides playing a commercial role, Hyphens will also be responsible for obtaining regulatory approvals for ella in the territories. Financial terms were not disclosed.
Launched in the European Union at the beginning of October under the trademark ellaOne, the product is based on a new chemical entity, ulipristal acetate. It is a first-in-class, orally active selective progesterone receptor modulator, and is the first molecule to have been specifically designed and developed for use as an oral emergency contraceptive. ella has been shown to have sustained efficacy up to five days after unprotected intercourse.
HRA Pharma expects to file for marketing approvals in countries worldwide. The company is also developing ulipristal acetate for other reproductive health indications outside of emergency contraception.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze